Low-dose subcutaneous tocilizumab to prevent disease progression in patients with moderate COVID-19 pneumonia and hyperinflammation

類似資料

• Low-dose subcutaneous tocilizumab to prevent disease progression in patients with moderate COVID-19 pneumonia and hyperinflammation
  著者:: Nicola Potere, 等
  出版事項: (2020-11-01)
• Interleukin-6 receptor blockade with subcutaneous tocilizumab improves coagulation activity in patients with COVID-19
  著者:: Di Nisio, Marcello, 等
  出版事項: (2021)
• Prevention of venous thromboembolism in hospitalized acutely ill medical patients: focus on the clinical utility of (low-dose) fondaparinux
  著者:: Di Nisio, Marcello, 等
  出版事項: (2013)
• Acute complications and mortality in hospitalized patients with coronavirus disease 2019: a systematic review and meta-analysis
  著者:: Potere, Nicola, 等
  出版事項: (2020)
• Analysis of peripheral blood lymphocyte subsets in critical patients at ICU admission: A preliminary investigation of their role in the prediction of sepsis during ICU stay
  著者:: Frattari, Antonella, 等
  出版事項: (2018)